Composition for regulating production of ribonucleic acid

[0001] The present disclosure generally relates to compositions for regulating production of ribonucleic acid (RNA). In particular, the present disclosure relates to compositions and methods for regulating gene expression and, therefore, production of micro-RNA.

[0002] Bioactive molecules, including enzymes, receptors, receptor agonists and antagonists, are necessary for the homeostatic control of biological systems.

[0003] When bioactive molecules are over-expressed, under-expressed or mis-expressed, homeostasis is lost, and disease is often the result.

[0004] Known approaches to the treatment of conditions whereby bioactive molecules are over or mis-expressed are the commercially available pharmaceutical products that bind to and block the production or effectiveness of one or more bioactive molecules.

[0005] Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in production of the target biomolecule by a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a cytokine. In some embodiments of the present disclosure, the target biomolecule is a pro-inflammatory cytokine, such as tumor necrosis factor alpha (TNF-alpha).

[0006] In some embodiments of the present disclosure the compositions comprise vector DNA that includes one or more an insert sequences of nucleic acids that encode for the production of miRNA and a backbone sequence of nucleic acids that facilitates introduction of the one or more insert sequences into one or more of a subject's cells where it is expressed and/or replicated. Expression of the one or more insert sequences by one or more cells of the subject results in an increased production of the miRNA and, therefore, decreased translation of the target biomolecule by one or more of the subject's cells.

[0007] Some embodiments of the present disclosure relate to compositions that upregulate the production of miRNA that degrades, or causes degradation of, or inactivates or causes the inactivation of the target mRNA of the target biomolecule.

[0008] Some embodiments of the present disclosure relate to compositions that can be used as a therapy or a treatment for a subject that has a condition whereby the target biomolecule is over or mis-expressed.

[0009] Some embodiments of the present disclosure relate to a recombinant plasmid (RP). In some embodiments of the present disclosure, the RP comprises a nucleotide sequence of SEQ ID No. 1. The RP comprises a nucleotide sequence encoding one or more nucleotide sequences encoding a miRNA sequence that targets mRNA of tumor necrosis alpha TNF-alpha; and an inverted terminal repeat.

[0010] Some embodiments of the present disclosure relate to a cassette, which may also be referred to as an insert, for use with an RP, wherein the cassette comprises a nucleotide sequence of SEQ ID No. 2. When the cassette with SEQ ID No. 2 is included in the RP and the RP is administered to a subject, one or more of the subject's cells will upregulate production of miRNA that degrades, or causes degradation of, or inactivates or causes the inactivation of the target mRNA of the target biomolecule. For example, the target biomolecule may be TNF-alpha.

[0011] Some embodiments of the present disclosure relate to a cassette for use with an RP, wherein the cassette comprises a nucleotide sequence of SEQ ID No. 3. When the cassette with SEQ ID No. 3 is included in the RP and the RP is administered to a subject, one or more of the subject's cells will upregulate production of at least a portion of a miRNA sequence that degrades, or causes degradation of, or inactivates or causes the inactivation of the target mRNA of the target biomolecule. For example the target biomolecule may be TNF-alpha.

[0012] Some embodiments of the present disclosure relate to a cassette for use with an RP, wherein the cassette comprises a nucleotide sequence of SEQ ID No. 4. When the cassette with SEQ ID No. 4 is included in the RP and the RP is administered to a subject, one or more of the subject's cells will upregulate production of at least a portion of a miRNA sequence that degrades, or causes degradation of, or inactivates or causes the inactivation of the target mRNA of the target biomolecule. For example, the target biomolecule may be TNF-alpha.

[0013] Some embodiments of the present disclosure relate to a cassette for use with an RP, wherein the cassette comprises a nucleotide sequence of SEQ ID No. 5. When the cassette with SEQ ID No. 5 is included in the RP and the RP is administered to a subject, one or more of the subject's cells will upregulate production of at least a portion of a miRNA sequence that degrades, or causes degradation of, or inactivates or causes the inactivation of the target mRNA of the target biomolecule. For example, the target biomolecule may be TNF-alpha.

[0014] Some embodiments of the present disclosure relate to a method of making an composition/target cell complex. The method comprising a step of administering a RP comprising SEQ ID No. 1 to a target cell for forming the composition/target cell complex, wherein the composition/target cell complex causes the target cell to increase production of a one or more sequences of micro ribonucleic acid (miRNA) that decreases production of a target biomolecule.

[0015] Embodiments of the present disclosure relate to at least one approach for inducing endogenous production of one or more sequences of miRNA that target and silence mRNA of a target biomolecule, for example the TNF-alpha protein. A first approach utilizes gene vectors containing nucleotide sequences for increasing the endogenous production one or more sequences of miRNA, complete or partial sequences, that target and silence the mRNA of TNF-alpha, which can be administered to a subject to increase the subject' s production of one or more sequences of the miRNA.

[0029] Unless defined otherwise, all technical and scientific terms used herein have the meanings that would be commonly understood by one of skill in the art in the context of the present description. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.

[0030] As used herein, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. For example, reference to “an composition” includes one or more compositions and reference to “a subject” or “the subject” includes one or more subjects.

[0031] As used herein, the terms “about” or “approximately” refer to within about 25%, preferably within about 20%, preferably within about 15%, preferably within about 10%, preferably within about 5% of a given value or range. It is understood that such a variation is always included in any given value provided herein, whether or not it is specifically referred to.

[0032] As used herein, the term “activity” is used interchangeably with the term “functionality” and both terms refer to the physiologic action of biomolecule.

[0033] As used herein, the term “composition” refers to a substance that, when administered to a subject, causes one or more chemical reactions and/or one or more physical reactions and/or or one or more physiological reactions and/or one or more immunological reactions in the subject. In some embodiments of the present disclosure, the composition is a plasmid vector.

[0034] As used herein, the term “ameliorate” refers to improve and/or to make better and/or to make more satisfactory.

[0035] As used herein, the term “biomolecule” refers to a carbohydrate, a protein, an amino acid sequence, a nucleic acid, a lipid, a primary metabolite, a secondary metabolite or another metabolite that is found within a subject. A biomolecule may be endogenous or exogenous to a subject.

[0036] As used herein, the term “cell” refers to a single cell as well as a plurality of cells or a population of the same cell type or different cell types. Administering an composition to a cell includes in vivo, in vitro and ex vivo administrations and/or combinations thereof.

[0037] As used herein, the term “complex” refers to an association, either direct or indirect, between one or more particles of an composition and one or more target cells. This association results in a change in the metabolism of the target cell. As used herein, the phrase “change in metabolism” refers to an increase or a decrease in the one or more target cells' production of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), one or more proteins, and/or any post-translational modifications of one or more proteins.

[0038] As used herein, the term “endogenous” refers to the production and/or modification of a molecule that originates within a subject.

[0039] As used herein, the term “exogenous” refers to a molecule that is within a subject but that did not originate within the subject. As used herein, the terms “production”, “producing” and “produce” refer to the synthesis and/or replication of DNA, the transcription of one or more sequences of RNA, the translation of one or more amino acid sequences, the post-translational modifications of an amino acid sequence, and/or the production of one or more regulatory molecules that can influence the production and/or functionality of an effector molecule or an effector cell. For clarity, “production” is also be used herein to refer to the functionality of a regulatory molecule, unless the context reasonably indicates otherwise.

[0040] As used herein, the term “subject” refers to any therapeutic target that receives the composition. The subject can be a vertebrate, for example, a mammal including a human. The term “subject” does not denote a particular age or sex. The term “subject” also refers to one or more cells of an organism, an in vitro culture of one or more tissue types, an in vitro culture of one or more cell types, ex vivo preparations, and/or a sample of biological materials such as tissue and/or biological fluids.

[0041] As used herein, the term “target cell” refers to one or more cells and/or cell types that are deleteriously affected, either directly or indirectly, by a dysregulated immune system and/or a disease process. The term “target cell” also refers to cells that are not deleteriously affected but that are the cells in which it is desired that the composition interacts.

[0042] As used herein, the term “therapeutically effective amount” refers to the amount of the composition used that is of sufficient quantity to ameliorate, treat and/or inhibit one or more of a disease, disorder or a symptom thereof. The “therapeutically effective amount” will vary depending on the composition used, the route of administration of the composition and the severity of the disease, disorder or symptom thereof. The subject's age, weight and genetic make-up may also influence the amount of the composition that will be a therapeutically effective amount.

[0043] As used herein, the terms “treat”, “treatment” and “treating” refer to obtaining a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing an occurrence of a disease, disorder or symptom thereof and/or the effect may be therapeutic in providing a partial or complete amelioration or inhibition of a disease, disorder, or symptom thereof. Additionally, the term “treatment” refers to any treatment of a disease, disorder, or symptom thereof in a subject and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) ameliorating the disease.

[0044] As used herein, the terms “unit dosage form” and “unit dose” refer to a physically discrete unit that is suitable as a unitary dose for patients. Each unit contains a predetermined quantity of the composition and optionally, one or more suitable pharmaceutically acceptable carriers, one or more excipients, one or more additional active ingredients, or combinations thereof. The amount of composition within each unit is a therapeutically effective amount.

[0045] Where a range of values is provided herein, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also, encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.

[0046] In some embodiments of the present disclosure, an composition is a recombinant plasmid (RP) for introducing genetic material, such as one or more nucleotide sequences, into a target cell for reproduction or transcription of an insert that comprises one or more nucleotide sequences that are carried within the RP. In some embodiments of the present disclosure, the RP is delivered by a viral vector. In some embodiments of the present disclosure, the vector is an adeno-associated virus vector.

[0047] In some embodiments of the present disclosure, the insert comprises one or more nucleotide sequences that encode for production of at least one sequence of miRNA that decreases the production of target biomolecules. The miRNA may, directly or indirectly, bind to and degrade the target mRNA or otherwise inactivate the target mRNA so that less or none of the target-biomolecule protein is produced.

[0048] In some embodiments of the present disclosure, the target cytokine is a pro-inflammatory cytokine, meaning it has the physiologic effect of increasing inflammatory processes in the subject. In some embodiments of the present disclosure, the target cytokine is TNF-alpha. In some embodiments of the present disclosure, the target cytokine is an anti-inflammatory cytokine.

[0049] In some embodiments of the present disclosure, the insert comprises two or more nucleotide sequences that each encode one or more miRNA sequences that may be complimentary to and degrade, or cause degradation of, mRNA of the target biomolecule. In some embodiments of the present disclosure the insert comprises three nucleotide sequences that each encode a miRNA sequence that may be complimentary to and degrade, or causes degradation of, or inactivates or causes inactivation of mRNA of the target biomolecule.

[0050] In some embodiments of the present disclosure, the insert comprises one or more nucleotide sequences that each encode for a miRNA sequence that is complimentary to and degrades, or causes degradation of, or inactivates or causes inactivation of mRNA of the target biomolecule. In some embodiments of the present disclosure, the insert comprises two nucleotide sequences that each encode for miRNA that may be complimentary to and degrade, or causes degradation of, or inactivate, or causes inactivation of mRNA of the target biomolecule. In some embodiments of the present disclosure, the insert comprises three nucleotide sequences that each encode for miRNA that may be complimentary to and degrade, or causes degradation of, or inactivate, or causes inactivation of mRNA of the target biomolecule. In some embodiments of the present disclosure, the insert comprises more than three nucleotide sequences that each encode for miRNA that may be complimentary to and degrade, or causes degradation of, or inactivate, or causes inactivation of mRNA of the target biomolecule.

[0051] In some embodiments of the present disclosure, the composition can be administered to the subject by an intravenous route, an intramuscular route, an intraperitoneal route, an intrathecal route, an intravessical route, a topical route, an intranasal route, a transmucosal route, a pulmonary route, and combinations thereof.

[0052] In some embodiments of the present disclosure, the composition can be administered to the subject by pipetting a dose of the composition into an in vitro cell culture, perfusing or immersing an ex vivo cell or tissue preparation with a solution that comprises the composition, mixing a biological fluid sample with a solution or substrate that comprises the composition, or combinations thereof.

[0053] Some embodiments of the present disclosure relate to a composition that can be administered to a subject with a condition that results from, directly or indirectly, a dysregulated immune system. When a therapeutically effective amount of the composition is administered to the subject, the subject may change production and/or functionality of one or more immune system molecules. For example, the subject may decrease production and/or functionality of one or more immune system signaling molecules and/or one or more immune system effector molecules by changing the production of one or more sequences of DNA, one or more sequences of RNA and/or one or more proteins and/or one or more regulatory molecules that regulate the levels and/or functionality of the subject's immune system signaling molecules and/or immune system effector molecules.

[0054] In some embodiments of the present disclosure, the subject may respond to receiving the therapeutic amount of the composition by changing production and/or functionality of one or more intermediary molecules by changing production of one or more DNA sequences, one or more RNA sequences, and/or one or more proteins that regulate the levels and/or functionality of the one or more intermediary molecules. The one or more intermediary molecules regulate the subject's levels and/or functionality of the one or more biomolecules.

[0055] In some embodiments of the present disclosure, administering a therapeutic amount of the composition to a subject upregulates the production, functionality or both one or more sequences of miRNA that each target the mRNA of one or more target biomolecules. In some embodiments of the present disclosure, there are one, two three, four, five, six, seven, eight, nine or ten miRNA sequences that each are complimentary to and degrade, or cause degradation of, one biomolecule, such as TNF-alpha. In some embodiments of the present disclosure, the composition may comprise multiple copies of the same nucleotide sequence of miRNA.

[0056] In some embodiments of the present disclosure, the composition is an RP that may be used for gene therapy. The gene therapy is useful for increasing the subject's endogenous production of one or more sequences of miRNA that target the mRNA of a target biomolecule. For example, the RP can contain one or more nucleotide sequences that that cause increased production of one or more nucleotide sequences that cause an increased production of one or more miRNA sequences that that each are complimentary to and degrade, or cause degradation of, or inactivate, or cause inactivation of one biomolecule, such as TNF-alpha.

[0057] In some embodiments of the present disclosure, the delivery vehicle, also referred to as a vector, of the RP used for gene therapy is a virus that can be enveloped, or not (undeveloped), replication effective or not (replication ineffective), or combinations thereof. In some embodiments of the present disclosure, the vector is a virus that is not enveloped and not replication effective. In some embodiments of the present disclosure, the vector is a virus of the Paroviridae family. In some embodiments of the present disclosure, the vector is a virus of the genus Dependoparvaovirus. In some embodiments of the present disclosure, the vector is an adeno-associated virus (AAV). In some embodiments of the present disclosure, the vector is a recombinant AAV. In some embodiments of the present disclosure, the vector is a recombinant AAV6.2FF.

[0058] The embodiments of the present disclosure also relate to administering a therapeutically effective amount of the composition. In some embodiments of the present disclosure, the therapeutically effective amount of the composition that is administered to a patient is between about 10 and about 1×10¹⁶ TCID₅₀/kg (50% tissue culture infective dose per kilogram of the patient's body weight). In some embodiments of the present disclosure, the therapeutically effective amount of the composition that is administered to the patient is about 1×10¹³ TCID₅₀/kg. In some embodiments of the present disclosure, the therapeutically effective amount of the composition that is administered to a patient is measured in TPC/kg (total particle count of the composition per kilogram of the patient's body weight). In some embodiments the therapeutically effective amount of the composition is between about 10 and about 1×10¹⁶ TCP/kg.

[0059] Some embodiments of the present disclosure relate to an adenovirus associated virus (AAV) genome consisting of a RP that when operable inside a target cell will cause the target cell to produce a miRNA sequence that downregulates production of TNF-α. The AAV vector is comprised of AAV2 inverted terminal repeats (ITRs), a composite CASI promoter, a human growth hormone (HGH) signal peptide followed by a miR155 microRNA cassette containing three different siRNAs targeting murine TNF-60 , a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), and an SV40 polyA signal.

[0060]

SEQ ID No. 1 (whole RP):
cagcagctgc gcgctcgctc gctcactgag gccgcccggg caaagcccgg gcgtcgggcg	60
acctttggtc gcccggcctc agtgagcgag cgagcgcgca gagagggagt ggccaactcc	120
atcactaggg gttccttgta gttaatgatt aacccgccat gctacttatc tacgtagcca	180
tgctctagga cattgattat tgactagtgg agttccgcgt tacataactt acggtaaatg	240
gcccgcctgg ctgaccgccc aacgaccccc gcccattgac gtcaataatg acgtatgttc	300
ccatagtaac gccaataggg actttccatt gacgtcaatg ggtggagtat ttacggtaaa	360
ctgcccactt ggcagtacat caagtgtatc atatgccaag tacgccccct attgacgtca	420
atgacggtaa atggcccgcc tggcattatg cccagtacat gaccttatgg gactttccta	480
cttggcagta catctacgta ttagtcatcg ctattaccat ggtcgaggtg agccccacgt	540
tctgcttcac tctccccatc tcccccccct ccccaccccc aattttgtat ttatttattt	600
tttaattatt ttgtgcagcg atgggggcgg gggggggggg gggcgcgcgc caggcggggc	660
ggggcggggc gaggggcggg gcggggcgag gcggagaggt gcggcggcag ccaatcagag	720
cggcgcgctc cgaaagtttc cttttatggc gaggcggcgg cggcggcggc cctataaaaa	780
gcgaagcgcg cggcgggcgg gagtcgctgc gcgctgcctt cgccccgtgc cccgctccgc	840
cgccgcctcg cgccgcccgc cccggctctg actgaccgcg ttactaaaac aggtaagtcc	900
ggcctccgcg ccgggttttg gcgcctcccg cgggcgcccc cctcctcacg gcgagcgctg	960
ccacgtcaga cgaagggcgc agcgagcgtc ctgatccttc cgcccggacg ctcaggacag	1020
cggcccgctg ctcataagac tcggccttag aaccccagta tcagcagaag gacattttag	1080
gacgggactt gggtgactct agggcactgg ttttctttcc agagagcgga acaggcgagg	1140
aaaagtagtc ccttctcggc gattctgcgg agggatctcc gtggggcggt gaacgccgat	1200
gatgcctcta ctaaccatgt tcatgttttc tttttttttc tacaggtcct gggtgacgaa	1260
caggcctagc atcgataccg tcgtatgtgc tggaggcttg ctgaaggctg tatgctggct	1320
cctccacttg gtggtttggt tttggcctct gactgaccaa accacagtgg aggagccagg	1380
acacaaggcc tgttactagc actcacatgg aacaaatggc ctctagcctg gaggcttgct	1440
gaaggctgta tgctgtttct cctggtatga gatagcgttt tggcctctga ctgacgctat	1500
ctcaccagga gaaacaggac acaaggcctg ttactagcac tcacatggaa caaatggcct	1560
ctagcctgga ggcttgctga aggctgtatg ctgccgcaaa gtctaagtac ttgggttttg	1620
gcctctgact gacccaagta cagactttgc ggcaggacac aaggcctgtt actagcactc	1680
acatggaaca aatggcctct ctagaataat caacctctgg attacaaaat ttgtgaaaga	1740
ttgactggta ttcttaacta tgttgctcct tttacgctat gtggatacgc tgctttaatg	1800
cctttgtatc atgctattgc ttcccgtatg gctttcattt tctcctcctt gtataaatcc	1860
tggttgctgt ctctttatga ggagttgtgg cccgttgtca ggcaacgtgg cgtggtgtgc	1920
actgtgtttg ctgacgcaac ccccactggt tggggcattg ccaccacctg tcagctcctt	1980
tccgggactt tcgctttccc cctccctatt gccacggcgg aactcatcgc cgcctgcctt	2040
gcccgctgct ggacaggggc tcggctgttg ggcactgaca attccgtggt gttgtcgggg	2100
aaatcatcgt cctttccttg gctgctcgcc tgtgttgcca cctggattct gcgcgggacg	2160
tccttctgct acgtcccttc ggccctcaat ccagcggacc ttccttcccg cggcctgctg	2220
ccggctctgc ggcctcttcc gcgtcttcgc cttcgccctc agacgagtcg gatctccctt	2280
tgggccgcct ccccgcctaa gcttatcgat accgtcgaga tctaacttgt ttattgcagc	2340
ttataatggt tacaaataaa gcaatagcat cacaaatttc acaaataaag catttttttc	2400
actgcattct agttgtggtt tgtccaaact catcaatgta tcttatcatg tctggatctc	2460
gacctcgact agagcatggc tacgtagata agtagcatgg cgggttaatc attaactaca	2520
aggaacccct agtgatggag ttggccactc cctctctgcg cgctcgctcg ctcactgagg	2580
ccgggcgacc aaaggtcgcc cgacgcccgg gctttgcccg ggcggcctca gtgagcgagc	2640
gagcgcgcag ctggcgtaat agcgaagagg cccgcaccga tcgcccttcc caacagttgc	2700
gcagcctgaa tggcgaatgg cgattccgtt gcaatggctg gcggtaatat tgttctggat	2760
attaccagca aggccgatag tttgagttct tctactcagg caagtgatgt tattactaat	2820
caaagaagta ttgcgacaac ggttaatttg cgtgatggac agactctttt actcggtggc	2880
ctcactgatt ataaaaacac ttctcaggat tctggcgtac cgttcctgtc taaaatccct	2940
ttaatcggcc tcctgtttag ctcccgctct gattctaacg aggaaagcac gttatacgtg	3000
ctcgtcaaag caaccatagt acgcgccctg tagcggcgca ttaagcgcgg cgggtgtggt	3060
ggttacgcgc agcgtgaccg ctacacttgc cagcgcccta gcgcccgctc ctttcgcttt	3120
cttcccttcc tttctcgcca cgttcgccgg ctttccccgt caagctctaa atcgggggct	3180
ccctttaggg ttccgattta gtgctttacg gcacctcgac cccaaaaaac ttgattaggg	3240
tgatggttca cgtagtgggc catcgccctg atagacggtt tttcgccctt tgacgttgga	3300
gtccacgttc tttaatagtg gactcttgtt ccaaactgga acaacactca accctatctc	3360
ggtctattct tttgatttat aagggatttt gccgatttcg gcctattggt taaaaaatga	3420
gctgatttaa caaaaattta acgcgaattt taacaaaata ttaacgttta caatttaaat	3480
atttgcttat acaatcttcc tgtttttggg gcttttctga ttatcaaccg gggtacatat	3540
gattgacatg ctagttttac gattaccgtt catcgattct cttgtttgct ccagactctc	3600
aggcaatgac ctgatagcct ttgtagagac ctctcaaaaa tagctaccct ctccggcatg	3660
aatttatcag ctagaacggt tgaatatcat attgatggtg atttgactgt ctccggcctt	3720
tctcacccgt ttgaatcttt acctacacat tactcaggca ttgcatttaa aatatatgag	3780
ggttctaaaa atttttatcc ttgcgttgaa ataaaggctt ctcccgcaaa agtattacag	3840
ggtcataatg tttttggtac aaccgattta gctttatgct ctgaggcttt attgcttaat	3900
tttgctaatt ctttgccttg cctgtatgat ttattggatg ttggaattcc tgatgcggta	3960
ttttctcctt acgcatctgt gcggtatttc acaccgcata tggtgcactc tcagtacaat	4020
ctgctctgat gccgcatagt taagccagcc ccgacacccg ccaacacccg ctgacgcgcc	4080
ctgacgggct tgtctgctcc cggcatccgc ttacagacaa gctgtgaccg tctccgggag	4140
ctgcatgtgt cagaggtttt caccgtcatc accgaaacgc gcgagacgaa agggcctcgt	4200
gatacgccta tttttatagg ttaatgtcat gataataatg gtttcttaga cgtcaggtgg	4260
cacttttcgg ggaaatgtgc gcggaacccc tatttgttta tttttctaaa tacattcaaa	4320
tatgtatccg ctcatgagac aataaccctg ataaatgctt caataatatt gaaaaaggaa	4380
gagtatgagt attcaacatt tccgtgtcgc ccttattccc ttttttgcgg cattttgcct	4440
tcctgttttt gctcacccag aaacgctggt gaaagtaaaa gatgctgaag atcagttggg	4500
tgcacgagtg ggttacatcg aactggatct caacagcggt aagatccttg agagttttcg	4560
ccccgaagaa cgttttccaa tgatgagcac ttttaaagtt ctgctatgtg gcgcggtatt	4620
atcccgtatt gacgccgggc aagagcaact cggtcgccgc atacactatt ctcagaatga	4680
cttggttgag tactcaccag tcacagaaaa gcatcttacg gatggcatga cagtaagaga	4740
attatgcagt gctgccataa ccatgagtga taacactgcg gccaacttac ttctgacaac	4800
gatcggagga ccgaaggagc taaccgcttt tttgcacaac atgggggatc atgtaactcg	4860
ccttgatcgt tgggaaccgg agctgaatga agccatacca aacgacgagc gtgacaccac	4920
gatgcctgta gcaatggcaa caacgttgcg caaactatta actggcgaac tacttactct	4980
agcttcccgg caacaattaa tagactggat ggaggcggat aaagttgcag gaccacttct	5040
gcgctcggcc cttccggctg gctggtttat tgctgataaa tctggagccg gtgagcgtgg	5100
gtctcgcggt atcattgcag cactggggcc agatggtaag ccctcccgta tcgtagttat	5160
ctacacgacg gggagtcagg caactatgga tgaacgaaat agacagatcg ctgagatagg	5220
tgcctcactg attaagcatt ggtaactgtc agaccaagtt tactcatata tactttagat	5280
tgatttaaaa cttcattttt aatttaaaag gatctaggtg aagatccttt ttgataatct	5340
catgaccaaa atcccttaac gtgagttttc gttccactga gcgtcagacc ccgtagaaaa	5400
gatcaaagga tcttcttgag atcctttttt tctgcgcgta atctgctgct tgcaaacaaa	5460
aaaaccaccg ctaccagcgg tggtttgttt gccggatcaa gagctaccaa ctctttttcc	5520
gaaggtaact ggcttcagca gagcgcagat accaaatact gtccttctag tgtagccgta	5580
gttaggccac cacttcaaga actctgtagc accgcctaca tacctcgctc tgctaatcct	5640
gttaccagtg gctgctgcca gtggcgataa gtcgtgtctt accgggttgg actcaagacg	5700
atagttaccg gataaggcgc agcggtcggg ctgaacgggg ggttcgtgca cacagcccag	5760
cttggagcga acgacctaca ccgaactgag atacctacag cgtgagctat gagaaagcgc	5820
cacgcttccc gaagggagaa aggcggacag gtatccggta agcggcaggg tcggaacagg	5880
agagcgcacg agggagcttc cagggggaaa cgcctggtat ctttatagtc ctgtcgggtt	5940
tcgccacctc tgacttgagc gtcgattttt gtgatgctcg tcaggggggc ggagcctatg	6000
gaaaaacgcc agcaacgcgg cctttttacg gttcctggcc ttttgctggc cttttgctca	6060
catgttcttt cctgcgttat cccctgattc tgtggataac cgtattaccg cctttgagtg	6120
agctgatacc gctcgccgca gccgaacgac cgagcgcagc gagtcagtga gcgaggaagc	6180
ggaagagcgc ccaatacgca aaccgcctct ccccgcgcgt tggccgattc attaatg	6237

[0061]

SEQ ID No. 2(miRNA cassette):
ctggaggctt gctgaaggct gtatgctggc tcctccactt ggtggtttgg ttttggcctc	60
tgactgacca aaccacagtg gaggagccag gacacaaggc ctgttactag cactcacatg	120
gaacaaatgg cctctagcct ggaggcttgc tgaaggctgt atgctgtttc tcctggtatg	180
agatagcgtt ttggcctctg actgacgcta tctcaccagg agaaacagga cacaaggcct	240
gttactagca ctcacatgga acaaatggcc tctagcctgg aggcttgctg aaggctgtat	300
gctgccgcaa agtctaagta cttgggtttt ggcctctgac tgacccaagt acagactttg	360
cggcaggaca caaggcctgt tactagcact cacatggaac aaatggcctc tctagaa	417

[0062]

SEQ ID No. 3 (miRNA 1):
ctggaggctt gctgaaggct gtatgctggc tcctccactt ggtggtttgg ttttggcctc	60
tgactgacca aaccacagtg gaggagccag gacacaaggc ctgttactag cactcacatg	120
gaacaaatgg cctctagcc	139

[0063]

SEQ ID No. 4 (miRNA 2):
tggaggcttg ctgaaggctg tatgctgttt ctcctggtat gagatagcgt tttggcctct	60
gactgacgct atctcaccag gagaaacagg acacaaggcc tgttactagc actcacatgg	120
aacaaatggc ctctagc	137

[0064]

SEQ ID No. 5 (miRNA 3):
ctggaggctt gctgaaggct gtatgctgcc gcaaagtcta agtacttggg ttttggcctc	60
tgactgaccc aagtacagac tttgcggcag gacacaaggc ctgttactag cactcacatg	120
gaacaaatgg cctctctaga a	141

[0065]

	SEQ ID No. 6 (miRNA 1 anti-sense)
	gctcctccac ttggtggttt g	21

[0066]

	SEQ ID No. 7 (miRNA 1 sense)
	caaaccacag tggaggagc	19

[0067]

	SEQ ID No. 8 (miRNA 2 anti-sense)
	tttctcctgg tatgagatag c	21

[0068]

	SEQ ID No. 9 (miRNA 2 sense)
	gctatctcac caggagaaa	19

[0069]

	SEQ ID No. 10 (miRNA 3 anti-sense)
	ccgcaaagtc taagtacttg g	21

[0070]

	SEQ ID No. 11 (miRNA 3 sense)
	ccaagtacag actttgcgg	19

[0071] Expression cassettes for expressing a monoclonal antibody (mAb) and/or a protein and/or miRNA were synthesized. Each cassette contained a signal peptide, the variable heavy domain, the human IgG1 constant domain, the protein or the miRNA sequence followed by (when it is an Ab), a self-cleaving 2A peptide sequence, a signal peptide, the variable light domain and the human lambda constant domain. The synthesized mAb and/or protein and/or miRNA expression cassettes were cloned into the pAVA-00200 plasmid backbone containing the CASI promoter1, multiple cloning site (MCS), Woodchuck Hepatitis Virus post-transcriptional regulatory element (WPRE), Simian virus 40 (SV40) polyadenylation (polyA) sequence all flanked by the AAV2 inverted terminal repeats (ITR). pAVA-00200 was cut with the restriction enzymes KpnI and XbaI in the MCS and separated on a 1% agarose gel. The band of interest was excised and purified using a gel extraction kit. Each mAb and/or protein and/or miRNA expression cassette was amplified by PCR using Taq polymerase and the PCR products were gel purified and the bands on interest were also excised and purified using a gel extraction kit. These PCR products contained the mAb and/or protein and/or miRNA expression cassettes in addition to 15 base pair 5′ and 3′ overhangs that align with the ends of the linearized pAVA-00200 backbone. Using in-fusion cloning2, the amplified mAb or protein or miRNA expression cassettes are integrated with the pAVA-00200 backbone via homologous recombination. The resulting RP contained the following 5′ ITR, CASI promoter, monoclonal antibody or protein or miRNA expression cassette, WPRE, SV40 polyA and ITR 3′, per SEQ ID No. 1 and as shown in the contiguous portions of FIG. 1 through FIG. 12.